Lantern Pharma is trading 5.8% down at $3.26 amid a broader biotech sell-off and profit-taking that has weighed on high-beta names across the sector.
- The move appears driven primarily by sector rotation and risk-off sentiment in biotechnology rather than a new development at the company.
- There are no fresh company-specific headlines or new regulatory, clinical, or earnings events reported for the firm on July 14, 2026.